Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN818 with Olaparib in advanced solid tumors
NCT07156253Phase 1Recruiting
- Sponsor
- SynRx Therapeutics
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SYN818 in solid tumor (advanced stage), ovarian cancer and breast cancer, sponsored by SynRx Therapeutics. Primary endpoints: Maximum tolerated dose up to 3 years, Dose Limiting Toxicities and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
SYN818
03
Conditions
solid tumor (advanced stage)ovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT07156253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156253.